Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromfenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromfenac SCHEMBL34411 | 0.99 | ABCB11 (1.00) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL14861906 | 0.99 | ABCB11 (1.00) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL28429415 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL28895435 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL28429368 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL28429917 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL57090 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL4603047 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL28420990 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Bromfenac SCHEMBL15968905 | 0.97 | ABCB11 (0.97) | ABCB11LMNAPTGS1ADORA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250281395-A1 | OPHTHALMIC PREPARATION FOR TREATING MACULAR EDEMA, OPTIC NEURITIS AND NON-INFECTIOUS ENDOPHTHALMITIS THROUGH EYE DROP ADMINISTRATION | Chengdu Ruimu Biopharmaceuticals Co., Ltd. (CN) | 2025-09-11 | — | — | US | claimed |
| WO-2025081182-A1 | CITRATE-BASED OCULAR IMPLANTS AND POLYMERS | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-118615245-A | Sodium bromfenac eye drops and preparation method thereof | 武汉五景药业有限公司 | 2024-09-10 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240252429-A1 | EXTENDED-WEAR SILICONE HYDROGEL CONTACT LENSES AND USES THEREOF | OCUMEDIC, INC. | 2024-08-01 | — | — | US | claimed |
| CN-118319894-A | Pharmaceutical composition and application thereof | 广州润尔眼科生物科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-113698308-B | Synthesis method of bromfenac sodium | 山东辰龙药业有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-118121709-A | Ophthalmic pharmaceutical composition, and preparation method and application thereof | 山东序列生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-1681065-A1 | WATER-BASED COMPOSITION UNDERGOING REVERSIBLE THERMOGELATION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2006-07-19 | — | — | EP | claimed |
| WO-2005048979-A2 | PHARMACEUTICAL COMPOSITION HAVING CASING WITH MULTIPLE MICRO TABLETS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| EP-1443969-A2 | NON-INCLUSION CYCLODEXTRIN COMPLEXES | Decode Genetics EHF (IS) | 2004-08-11 | — | — | EP | claimed |
| US-20030138399-A1 | Anti-inflammatory therapy for inflammatory mediated infection | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-07-24 | — | — | US | claimed |
| US-20030109492-A1 | Non-inclusion cyclodextrin complexes | DECODE GENETICS EHF. (IS) | 2003-06-12 | — | — | US | claimed |
| WO-2003033025-A2 | CYCLODEXTRIN COMPLEXES | DECODE GENETICS EHF (IS) | 2003-04-24 | — | — | WO | claimed |
| JP-2002544210-A | — | — | 2002-12-24 | — | — | JP | claimed |
| CN-1353573-A | Anti-inflammatory therapy for inflammatory mediated infection | UNIV CALIFORNIA (US) | 2002-06-12 | — | — | CN | claimed |
| EP-1202620-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | The Regents of the University of California (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2000069255-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109492-A1 | Non-inclusion cyclodextrin complexes | SI, CNDP2, NONO | PTGS1 3863/4885PTGS2 4282/4885ABCB11 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.